Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant intravesical chemotherapy before TURBT in non-muscle-invasive bladder cancer
2024-512683-53-00Phase 4Authorised
- Sponsor
- Hospital Universitario La Paz
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisplatin, doxorubicin, mitomycin c, gemcitabine, docetaxel and 1 more in bladder cancer (2 arms), sponsored by Hospital Universitario La Paz. Primary endpoint: Early recurrence rate of non-muscle-invasive bladder cancer. Planned start Apr 2024; status: authorised.
02
Drugs
cisplatindoxorubicinmitomycin cgemcitabinedocetaxel
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-512683-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512683-53-00.